The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy
- PMID: 26264902
- PMCID: PMC4630248
- DOI: 10.1007/s10689-015-9827-7
The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy
Abstract
Women with an increased lifetime risk of ovarian cancer are advised to undergo risk-reducing salpingo-oophorectomy (RRSO) to reduce risk of adnexal cancer. We investigated the uptake of RRSO and evaluated the influence of personal medical history of (breast) cancer, risk-reducing mastectomy (RRM) and family history of ovarian and/or breast cancer on the RRSO decision. This single center retrospective observational cohort study was performed in a tertiary multidisciplinary clinic for hereditary cancer of the University Medical Centre Utrecht, The Netherlands. Women ≥35 years old with an estimated lifetime risk of ovarian cancer ≥10%, who had completed childbearing, were eligible for RRSO. Uptake and timing of RRSO were analyzed. Influence of personal medical history and family history on RRSO decision making, were evaluated with logistic regression. The study population consisted of 218 women (45.0% BRCA1 mutation carrier, 28.0% BRCA2 mutation carrier, 27.0% with familial susceptibility) with 87.2% RRSO uptake. The median age at RRSO was 44.5 (range 28-73) years. Of the women undergoing RRSO, 78.3% needed ≤3 consultations to reach this decision. Multivariable analysis showed a significant difference in RRSO uptake for women with a history of RRM [OR 3.66 95% CI (1.12-11.98)], but no significant difference in women with a history of breast cancer [OR 1.38 95% CI (0.50-3.79)], nor with a family history of ovarian and/or breast cancer [OR 1.10 95% CI (0.44-2.76)]. We conclude that RRSO counseling, without the alternative of screening, is effective. The uptake is increased in women with a history of RRM.
Keywords: BRCA1; BRCA2; Hereditary ovarian cancer; Prophylactic surgery uptake; Risk-reducing salpingo-oophorectomy.
Similar articles
-
Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.BJOG. 2012 Apr;119(5):527-36. doi: 10.1111/j.1471-0528.2011.03257.x. Epub 2012 Jan 20. BJOG. 2012. PMID: 22260402
-
Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.Fam Cancer. 2013 Dec;12(4):621-8. doi: 10.1007/s10689-013-9625-z. Fam Cancer. 2013. PMID: 23504064
-
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.Breast Cancer Res Treat. 2014 Nov;148(2):397-406. doi: 10.1007/s10549-014-3134-0. Epub 2014 Oct 14. Breast Cancer Res Treat. 2014. PMID: 25311111 Free PMC article.
-
The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.BMC Cancer. 2016 Jan 14;16:18. doi: 10.1186/s12885-015-2011-5. BMC Cancer. 2016. PMID: 26768420 Free PMC article. Review.
-
Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.Eur J Surg Oncol. 2022 Jun;48(6):1209-1216. doi: 10.1016/j.ejso.2022.02.019. Epub 2022 Feb 18. Eur J Surg Oncol. 2022. PMID: 35216860
Cited by
-
Uptake of Risk-Reducing Salpingo-Oophorectomy and Gynaecologic Surveillance Among Germline BRCA Pathogenic Variants Carriers.Cancer Med. 2024 Dec;13(23):e70321. doi: 10.1002/cam4.70321. Cancer Med. 2024. PMID: 39624976 Free PMC article.
-
Decision-making for Risk-reducing Salpingo-oophorectomy (RRSO) in Southeast Asian BRCA Mutation Carriers With Breast Cancer: A Qualitative Study.Int J Behav Med. 2022 Feb;29(1):1-13. doi: 10.1007/s12529-021-09984-y. Epub 2021 Mar 31. Int J Behav Med. 2022. PMID: 33791992
-
Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study).JMIR Res Protoc. 2021 Jan 22;10(1):e24414. doi: 10.2196/24414. JMIR Res Protoc. 2021. PMID: 33480862 Free PMC article.
-
Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial.BJOG. 2019 Feb;126(3):402-411. doi: 10.1111/1471-0528.15471. Epub 2018 Oct 23. BJOG. 2019. PMID: 30222235 Free PMC article. Clinical Trial.
-
Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis.BJOG. 2019 Feb;126(3):330-339. doi: 10.1111/1471-0528.15153. Epub 2018 Mar 15. BJOG. 2019. PMID: 29542222 Free PMC article.
References
-
- Antoniou A, Pharoah PD, Narod S, Risch HA, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. doi: 10.1086/375033. - DOI - PMC - PubMed
-
- Brohet RM, Velthuizen ME, Hogervorst FBL, Meijers-Heijboer HEJ, et al. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet. 2014;51:98–107. doi: 10.1136/jmedgenet-2013-101974. - DOI - PubMed
-
- Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, et al. Consortium of Investigators of Modifiers of BRCA1/2. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomark Prev. 2012;21(4):645–657. doi: 10.1158/1055-9965.EPI-11-0888. - DOI - PMC - PubMed
-
- van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010;124(3):643–651. doi: 10.1007/s10549-010-0805-3. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous